Life Science

Our Boronate resin is designed for the isolation ofribonucleotide and oligonucleotide RNA. The resin consists of boronic acid covalently linked to a polyacrylamide support that offers simple isolation of small molecular weight compounds that have

Our Boronate resin is designed for the isolation ofribonucleotide and oligonucleotide RNA. The resin consists of boronic acid covalently linked to a polyacrylamide support that offers simple isolation of small molecular weight compounds that have

A bacterial secondary metabolite which displays potent antiangiogenic activity, preventing tube formation in rat aorta explants (IC₅₀ = 0.8 nM) and inducing apoptosis in endothelial cells powerful inhibitor of both eukaryotic and

A bacterial secondary metabolite which displays potent antiangiogenic activity, preventing tube formation in rat aorta explants (IC₅₀ = 0.8 nM) and inducing apoptosis in endothelial cells powerful inhibitor of both eukaryotic and

A dipeptide boronic acid derivative that reversibly inhibits the 20S proteasome (Ki = 0.6 nM) drives cell cycle arrest and apoptosis in cancer cell lines and has applications in multiple myeloma and certain lymphomas, as well as other types of

A dipeptide boronic acid derivative that reversibly inhibits the 20S proteasome (Ki = 0.6 nM) drives cell cycle arrest and apoptosis in cancer cell lines and has applications in multiple myeloma and certain lymphomas, as well as other types of

A dipeptide boronic acid derivative that reversibly inhibits the 20S proteasome (Ki = 0.6 nM) drives cell cycle arrest and apoptosis in cancer cell lines and has applications in multiple myeloma and certain lymphomas, as well as other types of

A dipeptide boronic acid derivative that reversibly inhibits the 20S proteasome (Ki = 0.6 nM) drives cell cycle arrest and apoptosis in cancer cell lines and has applications in multiple myeloma and certain lymphomas, as well as other types of

An antagonist of the endothelin receptors type A (Ki = 6.5 nM) and type B (Ki = 340 nM) used, alone or in combination therapy, in the treatment of pulmonary arterial hypertension.

An antagonist of the endothelin receptors type A (Ki = 6.5 nM) and type B (Ki = 340 nM) used, alone or in combination therapy, in the treatment of pulmonary arterial hypertension.

An antagonist of the endothelin receptors type A (Ki = 6.5 nM) and type B (Ki = 340 nM) used, alone or in combination therapy, in the treatment of pulmonary arterial hypertension.

Best known as a potent dual inhibitor of c-Src and Abl (IC50 = 1.2 and 1.